Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiac Output and Fatigue in Friedreich's Ataxia
NCT07444333Not yet recruiting
- Start
- Apr 2026
- Primary completion
- Feb 2028
- Modality
- Small Molecules
01
Overview
Open-label trial of omaveloxolone in Friedreich ataxia (FA) (2 arms). Primary endpoints: Adverse events at 6 months, Maximal Oxygen Consumption at 6 months and 1 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
omaveloxolone
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on NCT07444333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07444333.